A liposomal subunit flu vaccine formulation

The Need: Addressing the Limitations of Current Flu Vaccines

Influenza epidemics and pandemics present significant challenges to public health and global economies. Existing flu vaccines are strain-specific, providing limited cross-protective immunity and often lack long-term effectiveness. Additionally, these vaccines may not be effective against unexpected strains that emerge during outbreaks, leading to reduced efficacy and potentially widespread infections. There is a crucial need for a more versatile and potent vaccine formulation capable of generating a broader immune response against various influenza strains.

The Technology: Innovative Antigen-Loaded Liposome Nanoparticles

The technology offered is an advanced immunogenic composition consisting of an antigen mixture comprising oligopeptides, encapsulated within liposome nanoparticles. Optionally, the formulation may include an adjuvant and appropriate excipients. The oligopeptides are designed to have a high degree of sequence identity to specific antigens associated with various influenza strains, thereby promoting a cross-protective immune response. Administered as a medicament or vaccine, this formulation aims to elicit a robust and long-lasting immune response against different influenza viruses.

Commercial Applications:

  • Influenza Vaccines: The technology can be employed to develop novel and improved influenza vaccines, capable of providing cross-protection against multiple strains of the virus.
  • Pandemic Preparedness: This technology enhances the ability to rapidly respond to emerging influenza strains during pandemics, reducing the risk of widespread infection and mitigating the impact on public health.
  • High-Risk Populations: The antigen-loaded liposome nanoparticles could be particularly valuable for vaccinating vulnerable populations, such as the elderly, young children, and individuals with compromised immune systems.
  • Global Health Initiatives: By addressing the limitations of current flu vaccines, this technology contributes to international efforts to prevent and control influenza outbreaks and epidemics.


  • Broad Cross-Protection: The technology's oligopeptide mixture and liposomal nanoparticle delivery enable a cross-protective immune response, enhancing the vaccine's effectiveness against diverse influenza strains.
  • Long-Term Immunity: By eliciting a potent and sustained immune response, the formulation offers extended protection, reducing the need for frequent revaccination.
  • Rapid Response Capability: The ability to incorporate new antigen sequences into the formulation allows for swift adjustments to address emerging flu strains, improving pandemic preparedness.
  • Enhanced Efficacy in High-Risk Groups: The formulation's ability to boost immune responses is beneficial for populations that may not respond optimally to traditional vaccines.
  • Public Health Impact: By providing a more effective and versatile vaccine, this technology has the potential to significantly reduce the burden of influenza on global public health systems.

In conclusion, this innovative technology represents a substantial advancement in the field of pharmaceutical and vaccine formulations, addressing the pressing need for improved influenza vaccines with broader cross-protection and longer-lasting immunity. By utilizing antigen-loaded liposome nanoparticles, this technology offers a promising solution to enhance public health preparedness and combat influenza epidemics and pandemics effectively.


Patent # Title Country
10,478,488 LIPOSOMAL FLU VACCINE FORMULATION United States of America

Loading icon